Tenaya Therapeutics, Inc. (TNYA)
NASDAQ: TNYA · Real-Time Price · USD
2.020
+0.190 (10.38%)
At close: Oct 9, 2025, 4:00 PM EDT
2.030
+0.010 (0.50%)
After-hours: Oct 9, 2025, 5:45 PM EDT
Tenaya Therapeutics Employees
Tenaya Therapeutics had 97 employees as of December 31, 2024. The number of employees decreased by 43 or -30.71% compared to the previous year.
Employees
97
Change (1Y)
-43
Growth (1Y)
-30.71%
Revenue / Employee
n/a
Profits / Employee
-$1,026,979
Market Cap
329.21M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -43 | -30.71% |
| Dec 31, 2023 | 140 | -1 | -0.71% |
| Dec 31, 2022 | 141 | 35 | 33.02% |
| Dec 31, 2021 | 106 | 31 | 41.33% |
| Dec 31, 2020 | 75 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TNYA News
- 7 days ago - Tenaya Therapeutics to Participate in Upcoming October Investor Conferences - GlobeNewsWire
- 21 days ago - Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Tenaya Therapeutics, Inc. (TNYA) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025 - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewsWire
- 2 months ago - Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed - GlobeNewsWire